Cancer Deals That Grabbed Headlines In 2020
Executive Summary
Despite the COVID-19 pandemic, 2020 has seen a hectic pace of cancer deal-making, including the two largest biopharma M&A deals of the year and 24 deals with upfront value of at least $100m.
You may also be interested in...
Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
Arrowhead Gets $120m From GSK For First-In-Class NASH RNAi Candidate
GSK enters the NASH race with a mid-stage candidate while Arrowhead gets to focus its R&D spending on candidates it may bring to market itself.
BioMarin’s Voxzogo Predicted For Blockbuster Sales, But Market Must Be Built
Very early launch numbers look good in France and Germany, but US launch will be more challenging due to a fragmented patient base, the company said. Launch price is a flat $899 per vial.